OAB is a common group of urinary symptoms that include a sudden, uncontrolled urge to urinate, frequent urination, and, in some patients, uncontrollable leakage of urine.1,2
OAB can have a significant negative impact on quality of life through interruptions in sleep, work, social life, and exercise, and may be associated with psychological challenges.2
The prevalence of OAB is high, as large, population-based studies estimate OAB rates from 7% to 27% in men and 9% to 43% in women.1
Standard first-line treatment for OAB is pharmacologic management with anti-muscarinics or β3-adrenoceptor agonists.3
However, in the case of an inadequate response, BOTOX® (onabotulinumtoxin A) administered via injection into the bladder is also an approved therapy for OAB.3
In October 2016, UroGen granted an exclusive worldwide license to Allergan to research, develop, manufacture, and commercialize pharmaceutical products formulated with our technology platform, RTGel™ and clostridial toxins, including BOTOX.
Allergan is currently evaluating an investigational drug formulation of BOTOX and RTGel for the treatment OAB.
BOTOX is a registered trademark of Allergan plc.